<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">In the GLOBE trial, grade 3 or 4 elevation in CK levels was observed in 12.9% of patients receiving telbivudine and in 4.1% patients of those receiving lamivudine for 104 weeks (p &lt; 0.001). Myopathy, has also been reported in 3 patients, all of whom had resolution of symptoms after telbivudine was discontinued
 <sup>
  <xref ref-type="bibr" rid="CR29">29</xref>
 </sup>.
</p>
